TW202334176A - 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 - Google Patents

新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 Download PDF

Info

Publication number
TW202334176A
TW202334176A TW111142076A TW111142076A TW202334176A TW 202334176 A TW202334176 A TW 202334176A TW 111142076 A TW111142076 A TW 111142076A TW 111142076 A TW111142076 A TW 111142076A TW 202334176 A TW202334176 A TW 202334176A
Authority
TW
Taiwan
Prior art keywords
compound
immunoconjugate
group
methyl
mmol
Prior art date
Application number
TW111142076A
Other languages
English (en)
Chinese (zh)
Inventor
理察 H 李
東駿 李
Original Assignee
美商艾德森特克斯治療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾德森特克斯治療股份有限公司 filed Critical 美商艾德森特克斯治療股份有限公司
Publication of TW202334176A publication Critical patent/TW202334176A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111142076A 2021-11-03 2022-11-03 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 TW202334176A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US63/275,177 2021-11-03
US202163295476P 2021-12-30 2021-12-30
US63/295,476 2021-12-30

Publications (1)

Publication Number Publication Date
TW202334176A true TW202334176A (zh) 2023-09-01

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142076A TW202334176A (zh) 2021-11-03 2022-11-03 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物

Country Status (9)

Country Link
EP (1) EP4426714A4 (https=)
JP (1) JP2024540402A (https=)
KR (1) KR20240110584A (https=)
AU (1) AU2022380491A1 (https=)
CA (1) CA3236944A1 (https=)
IL (1) IL312533A (https=)
MX (1) MX2024005342A (https=)
TW (1) TW202334176A (https=)
WO (1) WO2023081230A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067221A1 (zh) * 2023-09-26 2025-04-03 上海齐鲁制药研究中心有限公司 奥瑞他汀衍生物及其抗体药物偶联物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
CA3205824A1 (en) * 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Also Published As

Publication number Publication date
CA3236944A1 (en) 2023-05-11
EP4426714A1 (en) 2024-09-11
AU2022380491A1 (en) 2024-05-30
MX2024005342A (es) 2024-09-27
IL312533A (en) 2024-07-01
KR20240110584A (ko) 2024-07-15
WO2023081230A1 (en) 2023-05-11
EP4426714A4 (en) 2025-10-08
JP2024540402A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
JP2024038168A (ja) 生物活性分子コンジュゲート、その調製法及び使用
CA2852860C (en) Cytotoxic peptides and antibody drug conjugates thereof
RS64961B1 (sr) Derivati kamptotecina
ES2867749T3 (es) Conectores y su aplicación con respecto a los CAF
JP2020512270A (ja) ピロロベンゾジアゼピン二量体前駆体及びそのリガンド−リンカーコンジュゲート化合物
CA3027178A1 (en) Anti-egfr antibody drug conjugates
TWI712605B (zh) 含有cti藥效基團之雙功能性細胞毒性劑
EP3907226A2 (en) Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
TW202426456A (zh) 新穎的喜樹鹼類似物及其免疫綴合物
JP2018123122A (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
AU2024263367A1 (en) Antibody-drug conjugate
TW202400266A (zh) 配體藥物偶聯物及其應用
TW202334176A (zh) 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物
CA3198230A1 (en) Conjugate and use thereof
TW202328162A (zh) 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物
WO2024160176A1 (zh) 一类连接子药物及其抗体-药物偶联物的制备方法和应用
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40115429A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40117241A (zh) 新型澳瑞他汀类似物及其免疫偶联物
WO2026065268A1 (en) Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same
CN120513102A (zh) 一种抗体药物偶联物及其制备方法和用途
CN120957756A (zh) 稠环化合物及其制备方法和用途
WO2024193692A1 (zh) 连接子及其在配体药物偶联物中的应用